イスラエルでのC型肝炎治療に最適なクリニックと費用をご発見ください2026

Hepatitis C treatment in Israel achieves success rates exceeding 95% using modern direct-acting antiviral medications. National clinical data reveals recovery rates reaching 98.8% for patients following stabilized protocols. Undetectable viral loads are typically confirmed 12 weeks after completing the standard medication course.

• Success markers: Sustained virologic response (SVR) indicates successful virus elimination in 98% of cases.
• Modern protocols: Direct-acting antivirals outperform older interferon therapies, which only reached 78% success.
• High-risk groups: Targeted programs in challenging settings maintain success rates as high as 97.8%.
• Specialized expertise: Expert-led units at facilities like Sourasky Medical Center report 95% to 97% success.

Bookimed Expert Insight: Clinical data shows that Israeli specialists like Dr. Oren Shibolet and Dr. Rafael Bruck leverage over 40 years of experience to manage complex viral hepatitis cases. These experts often use rapid resistance testing and pangenotypic regimens to ensure high success rates across all genotypes. Patients benefit from this deep expertise at centers like Sourasky, which serves 1.8 million patients annually.

Patient Consensus: Patients describe the modern 8 to 12 week treatment as much easier than expected with minimal side effects. Many emphasize that starting with an early fibrosis scan significantly improves personal peace of mind during recovery.

Top-rated clinics for Hepatitis C in Israel include Sourasky Medical Center, Sheba Medical Center, and Hadassah University Medical Center. These JCI-accredited facilities utilize direct-acting antivirals (DAAs) and specialized liver units. Patients access world-renowned hepatologists and advanced diagnostic imaging for personalized treatment protocols with high success rates.

• Expert leadership: Dr. Oren Shebolet manages liver conditions with over 50 years of experience.
• Clinical excellence: Sourasky Medical Center is a Newsweek-ranked facility treating 400,000 patients annually.
• Viral specialization: Dr. Rafael Bruck treats Hepatitis B and C with 40+ years experience.
• Pediatric care: Dana-Dwek Children's Hospital provides specialized infectious disease services for pediatric patients.

Bookimed Expert Insight: While many choose Israel for its high 95%+ cure rates, the real advantage lies in the depth of clinical research at major centers. For example, Sourasky Medical Center operates 240 departments and performs 34,000 surgeries yearly. This volume ensures that specialists like Dr. Oren Shebolet, who has 100+ conference reports, stay at the forefront of evolving antiviral resistance patterns.

Patient Consensus: Patients note that direct-acting antivirals often achieve results in 8 to 12 weeks. Many emphasize getting genotype testing early to ensure the most effective medication combo is prescribed immediately.

A typical Hepatitis C treatment course using Direct-Acting Antivirals (DAA) in Israel lasts between 8 and 12 weeks. Specialized hepatology units achieve cure rates exceeding 95% using pan-genotypic regimens. Duration depends on the specific virus genotype, liver fibrosis stage, and previous treatment history.

• 8-week course: Standard for treatment-naive patients without cirrhosis using regimens like Glecaprevir/Pibrentasvir.
• 12-week course: Required for patients with compensated cirrhosis or those repeating therapy.
• Response-guided therapy: Advanced modeling may shorten treatment to 6 weeks for eligible patients.
• Monitoring protocol: Patients undergo weekly bloodwork during the first month to track response.
• Cure confirmation: Viral load testing occurs 12 weeks after completing the full medication course.

Bookimed Expert Insight: Sourasky Medical Center provides access to world-renowned experts like Dr. Oren Shibolet and Prof. Rafael Bruck. With over 40 years of experience each, these specialists manage over 1,800,000 patients annually. Their high volume allows for precise, data-driven decisions on whether a patient safely qualifies for the shorter 8-week protocol.

Patient Consensus: Patients note that while fatigue is common during the first month, it typically fades quickly. They emphasize getting a fibrosis scan early to see if they qualify for shorter treatment windows.

Israel provides full access to the latest pan-genotypic Direct-Acting Antiviral (DAA) medications. These drugs have been covered under the National Health Act since 2015. Access expanded in 2018 to include all patients regardless of liver disease severity or genotype.

• Available regimens: Epclusa, Mavyret, and Vosevi are standard treatments in Israel.
• Universal eligibility: All confirmed patients receive treatment through health maintenance organizations.
• Simplified testing: Genotype testing is no longer required before starting pan-genotypic therapy.
• Expert oversight: Specialists like Dr. Oren Shebolet manage complex chronic liver conditions.

Bookimed Expert Insight: Israeli hepatology centers like Sourasky Medical Center offer a distinct advantage for international patients. Specialists such as Dr. Rafael Bruck have over 40 years of experience managing viral hepatitis. These high-volume centers treat over 1,000,000 patients annually and provide rapid access to medication. While citizens use the public system, private patients often receive these specialized antiviral drugs within 24 hours.

Patient Consensus: Patients note that while the public system is efficient for residents, private options provide much faster access. Many suggest completing a Fibroscan early to bypass administrative delays when requesting specific pan-genotypic regimens.

First consultations for Hepatitis C in Israel should focus on clinical staging and genomic accuracy. Patients must confirm their specific viral genotype and current viral load. These metrics dictate the selection of direct-acting antivirals (DAAs) and the total duration of the treatment protocol.

• Diagnostic confirmation: Ask for your specific viral genotype and current quantitative viral load results.
• Fibrosis staging: Inquire if a FibroScan or biopsy is necessary to determine liver scarring levels.
• Treatment selection: Discuss why a specific direct-acting antiviral (DAA) regimen is recommended over alternatives.
• Success metrics: Confirm the timeline for sustained virological response (SVR) testing to verify a cure.

Bookimed Expert Insight: Data from leading Israeli centers like Sourasky Medical Center shows a high degree of specialization. Dr. Oren Shibolet and Dr. Rafael Bruck bring 40 to 50+ years of experience respectively. When consulting such senior experts, ask about their specific SVR success rates for your genotype. High-volume centers often have deeper experience with complex cases involving co-infections or previous treatment resistance.

Patient Consensus: Patients emphasize the need to clarify the difference between national success averages and your individual prognosis. It is important to ask about practical side effects like brain fog or fatigue to plan your daily schedule during the medication course.

Hepatitis C treatment in Israel achieves a 96.5% cure rate through national elimination programmes. Specialists provide oral direct-acting antivirals (DAAs) that target the virus directly. These medications yield success rates up to 98.8% in targeted clinical settings. Most patients clear the infection within 8 to 12 weeks.

• Treatment efficacy: Modern DAA regimens report a 96.5% validated cure rate.
• Medication type: Doctors use pan-genotypic antivirals like sofosbuvir and velpatasvir.
• Clinical benchmarks: Success requires Sustained Virologic Response (SVR) 12 weeks after therapy.
• Expert leadership: Dr Rafael Bruck at Sourasky Medical Center has over 40 years of experience.

Bookimed Expert Insight: Israeli hepatology units often integrate electronic health records with real-time viral load tracking. Prof. Dr Oren Shebolet at Sourasky Medical Center leads a specialised liver unit. This high-volume environment ensures specialists manage complex genotypes and advanced fibrosis with tailored protocols.

Patient Consensus: Patients highlight that modern antivirals cause only mild fatigue or headaches. They suggest arranging SVR12 testing in Australia to confirm the virus is permanently cleared after returning home.

Patients with complex co-infections are eligible and often prioritised for Hepatitis C treatment in Israel. Modern Direct-Acting Antiviral (DAA) medications allow specialists to treat individuals with concurrent HIV or Hepatitis B. Success rates for co-infected patients now match those with Hepatitis C alone.

• Priority status: Co-infections accelerate liver damage, making immediate DAA therapy a clinical priority.
• HIV management: Specialists coordinate Hepatitis C drugs with antiretroviral therapy to ensure safety.
• Hepatitis B safety: Doctors monitor for virus reactivation and may provide preventative antiviral medication.
• Expert oversight: Leading hepatologists like Dr Rafael Bruck manage complex cases at Sourasky Medical Center.

Bookimed Expert Insight: Israeli liver units offer a unique advantage by housing infectious disease and hepatology experts together. Dr Oren Shebolet at Sourasky Medical Center leads a specialised liver unit within a facility treating over 1,800,000 patients annually. This massive volume ensures specialists have handled virtually every possible drug interaction or complex case type.

Patient Consensus: Patients note that having a history of multiple infections does not automatically rule out treatment. They emphasize the need to provide a full medication list to ensure safety in Israel.

Pre-treatment liver assessment in Israel involves a detailed diagnostic workup to measure viral load and organ damage. Specialists use blood panels, FibroScan technology, and advanced imaging to stage Hepatitis C. These tests ensure the liver can process antiviral medications safely before treatment starts.

• Specialist consultation: Patients meet senior hepatologists like Dr Rafael Bruck at Sourasky Medical Center.
• Viral load testing: Blood tests quantify Hepatitis C RNA to determine the infection severity.
• FibroScan staging: Non-invasive elastography measures liver stiffness to detect scarring or cirrhosis accurately.
• Liver function panel: Tests check enzyme levels and protein synthesis to evaluate metabolic health.

Bookimed Expert Insight: Israeli liver units often integrate metabolic research with clinical care. Dr Oren Shibolet leads the Liver Unit at Sourasky, bringing over 50 years of experience. This deep expertise ensures patients receive the most effective antiviral combinations based on their specific viral genotype and liver health.

Patient Consensus: Patients note the diagnostic process in Israel is fast. They appreciate the clear explanations from doctors about how test results impact their medication schedule.

Israeli specialists prescribe direct-acting antivirals (DAAs) including Epclusa, Mavyret, and Vosevi to treat Hepatitis C. These oral medications target the virus directly. They achieve cure rates over 95% within 8 to 12 weeks. Specialists at JCI-accredited centres like Sourasky Medical Center manage these protocols.

• Pan-genotypic therapies: Epclusa and Mavyret treat all major Hepatitis C virus strains effectively.
• Triple-drug regimens: Vosevi serves as a secondary option if initial antiviral treatments fail.
• Non-invasive staging: Clinics use FIB-4 blood tests to assess liver health without biopsies.
• Specialist expertise: Professors like Dr Rafael Bruck apply latest schemes to eliminate viral manifestations.

Bookimed Expert Insight: Israeli hepatology units stand out because their lead specialists often hold 40+ years of experience. At Sourasky Medical Center, Dr Oren Shebolet and Dr Rafael Bruck lead units that treat over 400,000 patients annually. This massive patient volume means these doctors have handled virtually every complex case type imaginable.

Patient Consensus: Patients note that Israel uses modern antiviral tablets instead of older interferon injections. They appreciate the shorter 8-week cycles and the lack of major side effects during treatment.

Modern Hepatitis C treatment in Israel typically lasts 8 to 12 weeks. Most patients complete therapy within 12 weeks using direct-acting antiviral medications. Complex cases involving advanced cirrhosis may require 16 to 24 weeks. Specialists confirm the viral clearance 12 weeks after finishing the course.

• Standard duration: Most patients require 12 weeks of daily oral tablet therapy.
• Shortened course: Some patients without liver damage may qualify for 8-week protocols.
• Complex cases: Previous failed treatments or severe scarring may extend therapy to 24 weeks.
• Final clearance: A PCR blood test 12 weeks post-treatment confirms a permanent cure.

Bookimed Expert Insight: Israeli hepatologists like Dr Rafael Bruck at Sourasky Medical Center leverage over 40 years of experience to customise antiviral protocols. While standard courses are 12 weeks, specialists here often use advanced digital imaging to assess liver health. This precise mapping helps determine if a patient safely qualifies for the shorter 8-week regimen.

Patient Consensus: Patients in Israel find the daily tablet routine far easier than older injections. They emphasise that strict adherence to the daily schedule is vital for a successful cure. Most note that the follow-up blood test provides the ultimate peace of mind after finishing the medication.